Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Recruiting

Phase 2

Phase 3

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Sponsor:

AMO Pharma Limited

Code:

NCT05004129

Conditions

Congenital Myotonic Dystrophy

Eligibility Criteria

Sex: All

Age: 6 - 45

Healthy Volunteers: Not accepted

Interventions

Tideglusib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information